28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

Phase 3 ◽

Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.99 ◽

2020 ◽

Vol 4 (6) ◽

pp. s99

Author(s):

Jonathan Silverberg ◽

Andrew Pink ◽

Christina Olsen ◽

Stephan Weidinger

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Abstract not available.

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(17)31191-1 ◽

2017 ◽

Vol 389 (10086) ◽

pp. 2287-2303 ◽

Cited By ~ 364

Author(s):

Andrew Blauvelt ◽

Marjolein de Bruin-Weller ◽

Melinda Gooderham ◽

Jennifer C Cather ◽

Jamie Weisman ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Faculty Opinions recommendation of Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727591680.793534051 ◽

2017 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.054 ◽

2020 ◽

Vol 83 (5) ◽

pp. 1282-1293 ◽

Cited By ~ 10

Author(s):

Amy S. Paller ◽

Elaine C. Siegfried ◽

Diamant Thaçi ◽

Andreas Wollenberg ◽

Michael J. Cork ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded

Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.102 ◽

2020 ◽

Vol 4 (6) ◽

pp. s102

Author(s):

Stephan Weidinger ◽

Jonathan Silverberg ◽

Darryl Toth ◽

Thomas Bieber ◽

Andrew Alexis ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Abstract not available.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)00589-4 ◽

2021 ◽

Cited By ~ 1

Author(s):

Kristian Reich ◽

Henrique D Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Faculty Opinions recommendation of Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727591680.793555533 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

JAAD International ◽

10.1016/j.jdin.2021.11.001 ◽

2022 ◽

Vol 6 ◽

pp. 27-36

Author(s):

Norito Katoh ◽

Yukihiro Ohya ◽

Hiroyuki Murota ◽

Masanori Ikeda ◽

Xiaofei Hu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Blind Study ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

P67: LONG-TERM MANAGEMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH DUPILUMAB AND CONCOMITANT TOPICAL CORTICOSTEROIDS: A 1-YEAR RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL (CHRONOS)

Internal Medicine Journal ◽

10.1111/imj.67_13578 ◽

2017 ◽

Vol 47 ◽

pp. 25-25 ◽

Cited By ~ 5

Author(s):

A Blauvelt ◽

M Gooderham ◽

P Foley ◽

Griffiths CEM ◽

JC Cather ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽